September 17, 2015

Aurobindo Pharma’s received approval from the Food and Drug Administration this week for its generic of Roxane Laboratories’ Dolophine (methadone HCL) tablets. 

September 11, 2015

Egalet Corporation on Thursday launched (oxycodone HCI) in the U.S.

August 19, 2015

A study conducted by researchers at Johns Hopkins Bloomberg School of Public Health has found that Florida’s legislative efforts to curb opioid abuse seem to be having their desired effect. 

August 17, 2015

The website includes sections about the importance of preventing abuse of prescription drugs and outlines the Food and Drug Administrations guidelines on abuse-deterrent labeling. 

July 23, 2015

A new coalition has formed to ensure safe access to over-the-counter pain relief remedies. The Protecting Access to Pain Relief Coalition officially launched on June 22 to help ensure that American consumers continue to have access to, and choice of, safe and effective pain relief, including acetaminophen.

July 6, 2015

The Food and Drug Administration recently approved Orkambi a new cystic fibrosis treatment that received designation from the FDA as a breakthrough therapy and as an orphan drug. 

June 24, 2015

Aurobindo Pharma Limited has announced that it has received final approval from the U.S. Food and Drug Administration for entacapone tablets USP, 200 mg, the generic equivalent to Comtan Tablets 200 mg.

June 10, 2015

Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility.

June 2, 2015
Aurobindo Pharma Limited has received approval from the Food and Drug Administration for its generic equivalent to Flagyl (metronidazole) tablets in 250- and 500-mg dosage strengths.  
May 26, 2015

Aurobindo Pharma has submitted an abbreviated new drug application for dolutegravir 50 mg to the Food and Drug Administration for the treatment of HIV.

April 14, 2015

Diplomat Pharmacy announced it will distribute Novartis' new medicine Jadenu, which is indicated to treat patients with chronic iron overload. 

April 1, 2015

Teva said it expects the product to be available to patients during second-quarter 2015.

March 31, 2015

The drug is Food and Drug Administration-approved to treat opioid-induced constipation in adults with chronic, non-cancer pain. 

March 11, 2015

Mylan expanded its portfolio of generic products with the U.S. launch of buprenorphine hydrochloride sublingual tablets in 2-mg and 8-mg strengths, the generic version of Subutex from Reckitt Benckiser.

February 25, 2015

In 10 years, the percentage of opioid analgesic users who used an opioid analgesic stronger than morphine increased from 17% to 37%, NCHS reported Wednesday. 

February 20, 2015

Actavis on Friday gained approval for a generic version of Reckitt Benckiser's Subutex, indicated for the treatment of opioid dependence.

February 3, 2015

Zogenix last week announced that the Food and Drug Administration approved a new formulation of the company's Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII.

January 30, 2015

Janssen Therapeutics on Thursday announced that the Food and Drug Administration has approved its Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets. The drug is used to treat human immunodeficiency virus in combination with other antiretovirals for treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions, according to the company.


January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 14, 2015

The University of Florida's Pharm.D. program recently released an infographic around the risks associated with acetaminophen use. 

December 30, 2014

Vertex Pharmaceuticals has announced that the Food and Drug Administration approved a supplemental new drug application for the use of Kalydeco (ivacaftor) in people with cystic fibrosis ages 6 years and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator gene.

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 11, 2014

Teva Pharmaceuticals on Thursday announced the availability of levalbuterol inhalation solution, USP (concentrate), a generic equivalent to Xopenex inhalation solution concentrate. 

December 2, 2014

Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII.